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Available online 14 November 2015AbstractObjectives: Diabetes mellitus (DM) causes secondary osteoporosis, which reduces bone mineral density (BMD) and bone strength. Akita mice
(AM) are DM model mice used to evaluate glucose metabolism. However, bone metabolism in AM remains unclear. The purpose of this study
was to evaluate BMD, bone strength, and serum sclerostin levels in AM.
Methods: Female AM and control mice (C57/BL/6NCrSlc; CM) were divided into four groups: (1) a CM group sacrificed at 14 (CM-14w; n ¼ 8)
or (2) 18 weeks of age (CM-18w; n ¼ 6); and (3) an AM group sacrificed at 14 (AM-14w; n ¼ 9) or (4) 18 weeks of age (AM-18w; n ¼ 6).
Blood glucose level, serum sclerostin level, total tibial BMD, and femoral shaft bone strength were evaluated at each time point.
Results: Blood glucose levels were significantly higher in AM than in CM (p < 0.001). Serum sclerostin levels were significantly lower in AM-
18w than in CM-18w (p < 0.001). BMD was significantly lower in AM-14w than in CM-14w (p ¼ 0.004). Stiffness of the femoral shaft was
significantly lower in AM-18w than in CM-14w (p ¼ 0.04). Body weight (r ¼ 0.608, p < 0.01) and maximum load (r ¼ 0.438, p < 0.05) were
significantly positively correlated with serum sclerostin levels, while blood glucose levels showed a significant negative correlation (r ¼ 0.708,
p < 0.01).
Conclusions: AM showed decreased BMD and bone strength with lower levels of serum sclerostin than CM.
© 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Osteoporosis is a systemic disease characterized by low
bone strength resulting in low bone mineral density (BMD)
and bone quality, and it is known to increase the risk of
fractures. There are many diseases related to osteoporosis, and
diabetes mellitus (DM) is especially important as a cause of
secondary osteoporosis. Understanding abnormal bone meta-
bolism in DM is necessary for those treating osteoporosis.* Corresponding author. Tel.: þ81 18 884 6148; fax: þ81 18 836 2617.
E-mail address: miyakosh@doc.med.akita-u.ac.jp (N. Miyakoshi).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).DM is divided into two types: type 1 and type 2. A meta-
analysis has demonstrated that both type 1 and 2 DM are
risk factors for proximal femoral fractures compared with non-
DM patients [1]. In type 1 DM, insulin secretion is decreased.
Insulin facilitates the differentiation of osteoblasts, so the loss
of BMD in type 1 DM is believed to be caused by insulin
deficiency, which leads to decreased bone formation [2].
However, the risk of fracture in type 1 DM is much higher than
that due to loss of BMD [3]. On the other hand, the BMD is
not necessarily low in type 2 DM compared with non-DM,
even though the risk of fracture is higher [4,5]. These
studies suggest that both type 1 and 2 DM accelerate bone
fragility independent of the loss of BMD.
Various animal models have been used to study diabetic
osteoporosis. Streptozotocin-induced diabetic rats (STZ rats)Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Several other DM model animals, such as WBN/Kob rats
and Goto-Kakizaki rats, were evaluated in previous reports
[7,8]. In the present study, Akita mice (AM) were evaluated
as a DM model to analyze the bone in DM. AM are
autochthonous transgenic model mice for DM, and they
show a strong lack of glucose tolerance [9]. The AM model
has been used to evaluate the complications of DM and
therapeutic effects, but there have been no studies of bone
metabolism in AM. To analyze bone metabolism in osteo-
porotic animal models, serum bone alkaline phosphatase
(BAP) and cross-linked N-telopeptide of type I collagen
(NTX) are commonly used as markers. In the present study,
serum sclerostin levels were measured in AM. An increase
in sclerostin is associated with a high fracture risk, regard-
less of bone metabolism turnover, but the mechanism re-
mains unclear [10]; thus, it is important to investigate the
relationship between hyperglycemia and serum sclerostin to
understand bone metabolism in DM. The purpose of this
study was to evaluate BMD and bone strength in AM and to
study bone metabolism in DM.
2. Materials and methods2.1. AnimalsTwelve-week-old female AM (Japan SLC, Inc., Shizuoka,
Japan) and C57/BL/6NCrSlc mice (CM; Japan SLC, Inc.) as
a control were used. They were housed in a controlled
environment at 22 C with a 12-h light/dark cycle. They were
pair-fed and allowed free access to water and standard food
(CE-2; CLEA Japan, Tokyo, Japan) containing 1.14% cal-
cium, 1.06% phosphorus, and 250 IU of vitamin D3 per
100 g.2.2. Experimental designThe mice were divided into four groups: (1) a CM group
sacrificed after 2 weeks of feeding (CM-14w: n ¼ 8); (2) an
AM group sacrificed after 2 weeks of feeding (AM-14w:
n ¼ 9); (3) a CM group sacrificed after 6 weeks of feeding
(CM-18w: n ¼ 6); and (4) an AM group sacrificed after 6
weeks of feeding (AM-18w: n ¼ 6). The mice were eutha-
nized under anesthesia with an intra-abdominal injection of
ketamine (Sankyo, Tokyo, Japan) and xylazine (Zenoaq,
Fukushima, Japan). After sacrificing, the blood and bilateral
femora and tibiae were harvested. The left tibiae were soaked
in 10% formalin and used for BMD measurement. The right
femora and serum were stored at 20 C. The right femora
were used for three-point bending tests to evaluate bone
strength, and the serum was used for biochemical parameter
measurements. The animal experimentation protocols were
approved by the Animal Committee of Akita University
Graduate School of Medicine. All animal experiments con-
formed to the Guidelines for Animal Experimentation of
Akita University.2.3. Biochemical parametersThe blood was collected from the inferior vena cava. After
measuring the blood glucose level (mg/dl) (Antsense III;
Horiba, Kyoto, Japan), the remaining blood samples were
centrifuged at 15,000 rpm for 20 min to separate the serum.
Serum sclerostin (pg/ml) was measured using an enzyme-
linked immunosorbent assay (ELISA) kit (Mouse Sclerostin
ELISA; ALPCO Diagnostics, Salem, NH, USA).2.4. Bone mineral density (BMD)Total BMD (mg/cm2) of the left tibia was measured by dual
energy X-ray absorptiometry (QDR-4500; Hologic Inc., Wal-
tham, MA, USA).2.5. Biomechanical analysisBone strength of the right femur was evaluated by a three-
point bending device using a mechanical testing machine
(MZ-500S; Maruto, Tokyo, Japan). The femur was placed
horizontally on a two-point holder (6-mm span) with the
anterior aspect facing up, and a load was applied on the
midshaft with a crosshead speed of 10 mm/min until fracture
occurred. The biomechanical analysis was performed to
calculate the maximum load (N) and stiffness (N/mm).2.6. Statistical analysesAll values are presented as means± standard deviation (SD).
Statistical analysis was performed using one-way analysis of
variance (ANOVA). Statistical differences among all groups
were compared using Scheffe's method for multiple compari-
sons. Spearman's rank correlation coefficient method was used
to evaluate the correlations between serum sclerostin level and
body weight, blood glucose level, BMD, and biomechanical
data. All statistical analyses were performed using Statistical
Package for the Biosciences software (SPBS v9.6) [11]. Values
of p less than 0.05 were considered significant.
3. Results3.1. Body weight (Table 1)Body weight was significantly lower for AM-18w than for
AM-14w (p ¼ 0.004) and CM-18w (p < 0.001). There was no
significant difference in body weight between CM-14w and
CM-18w.3.2. Blood glucose and serum sclerostin (Table 1)Blood glucose levels were significantly higher in the AM
groups than in the CM groups both at 14 weeks (p < 0.001)
and at 18 weeks (p < 0.001) of age. The serum sclerostin level
was significantly lower for AM-18w than for CM-18w
(p < 0.001).
Table 3
Table 1
Body weight, blood glucose level, and serum sclerostin level.
CM-14w (n ¼ 8) AM-14w (n ¼ 9) CM-18w (n ¼ 6) AM-18w (n ¼ 6) ANOVA
Body weight (g) 23.4 ± 0.5 22.5 ± 0.8 24.4 ± 1.3 20.7 ± 0.7a,b p < 0.001
Blood glucose (mg/dl) 172.6 ± 16.9 302.8 ± 61.5c 159.3 ± 21.8 392.7 ± 65.3b p < 0.001
Serum sclerostin (pg/ml) 307.2 ± 44.8 274.6 ± 42.7 367.2 ± 46.3 249.6 ± 30.8d p < 0.001
All values are mean ± SD.
AM: Akita mice, ANOVA: analysis of variance, CM: control mice.
a p ¼ 0.004 versus AM-14w.
b p < 0.001 versus CM-18w.
c p < 0.001 versus CM-14w.
d p < 0.001 versus CM-18w by Scheffe's multiple comparison method.
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Spearman's rank correlation coefficient (r) between the serum sclerostin level
and other parameters.
Serum sclerostin
r p
Body weight 0.608 <0.01
Blood glucose 0.708 <0.01
BMD 0.308 n.s.
Maximum load 0.438 <0.05
Stiffness 0.256 n.s.
BMD: bone mineral density, n.s.: not significant.The total tibial BMD of AM-14w, but not that of AM-18w,
was significantly lower than the total tibial BMD of CM-14w
(p ¼ 0.004). There were no significant differences in
maximum load on the three-point bending test between the
AM groups and the CM groups both at 14 weeks and at 18
weeks of age. Stiffness on the three-point bending test also
showed similar tendencies between the two groups, with
stiffness significantly smaller for AM-18w than for CM-14w
(p ¼ 0.04).3.4. Correlation between serum sclerostin and other
parameters (Table 3)On Spearman's rank correlation analysis, body weight
(r ¼ 0.608, p < 0.01) and maximum load (r ¼ 0.438, p < 0.05)
were significantly positively correlated with serum sclerostin.
BMD had a similar tendency, but it was not significant. In
contrast, blood glucose showed a significant negative corre-
lation with serum sclerostin (r ¼ 0.708, p < 0.01). Stiffness
and serum sclerostin had no significant correlation.
4. Discussion
AM, discovered by Koizumi in 1997, are non-obese dia-
betes model mice originating from C57/BL/6N mice [12]. AM
develop severe DM associated with hypoinsulinemia. They
develop obvious polydipsia and polyuria at approximately 10
weeks of age and then develop hydronephrosis until 40 weeks
of age. Young AM were used in this study because end-stage
DM can only be used to evaluate completed osteoporosis,
while early-stage DM has been considered useful for evalu-
ating the pathogenetic mechanism of diabetic osteoporosis.Table 2
BMD and biomechanical data.
CM-14w (n ¼ 8) AM-14w (n ¼ 9)
Total BMD (g/cm2) 0.056 ± 0.005 0.049 ± 0.002a
Biomechanical data
Maximum load (N) 19.0 ± 2.9 14.4 ± 4.6
Stiffness (N/mm) 90.4 ± 20.6 57.3 ± 29.8
All values are means ± SD.
AM: Akita mice, ANOVA: analysis of variance, BMD: bone mineral density, CM
a p ¼ 0.004 versus CM-14w.
b p ¼ 0.04 versus CM-14w by Scheffe's multiple comparison method.AM have been used as a model of type 1 DM [13], and they
have been used to evaluate the mechanisms of DM compli-
cations and therapeutic effects [9,14]. Kakoki et al. evaluated
BMD in AM and reported that BMD was significantly lower in
AM than in wild-type mice [15]. However, no advanced study
involving AM has yet been performed. Thus, BMD, bone
strength and bone metabolism in DM were evaluated in AM in
the present study.
The BMD tended to be lower in AM than in CM, but the
difference was not significant. In general, BMD is low in type
1 DM, while BMD is normal or higher in type 2 DM than in
normal subjects [3]. There are some previous studies that
evaluated BMD in DM model rats [16,17]. Matthew et al.
reported that rats with type 1 DM had a progressive loss of
trabecular BMD compared with control rats [18]. On the other
hand, Armas et al. reported that there was no significant dif-
ference in total hip BMD, which reflects cortical BMD, be-
tween type 1 DM and a control group [19]. In the present
study, total tibial BMD, which reflects cortical BMD, was
evaluated, so we similarly found no significant difference in
BMD between AM and CM. Alternatively, the AM were
young, so the effect of hyperglycemia might not have beenCM-18w (n ¼ 6) AM-18w (n ¼ 6) ANOVA
0.053 ± 0.002 0.051 ± 0.003 p ¼ 0.003
17.6 ± 1.6 14.4 ± 4.4 p ¼ 0.04
74.0 ± 23.8 50.1 ± 17.9b p ¼ 0.02
: control mice.
101K. Ohuchi et al. / Osteoporosis and Sarcopenia 1 (2015) 98e102reflected. Further evaluation of the cancellous BMD of older
AM would be needed to determine the effect of type 1 DM on
BMD.
In the three-point bending test, the maximum load was not
significantly different between AM and CM, while stiffness
was significantly lower in AM than in CM. There have been
only a few reports of the three-point bending test of long bones
in DM model rats [20]. Suzuki et al. reported that the ultimate
strength and stiffness were significantly lower in STZ rats than
in control rats [6]. On the other hand, Fowlkes et al. reported
that both peak force and stiffness were similar in STZ rats and
control rats [21]. Regarding the differences in maximum load
and stiffness, Saito et al. reported that bone volume was the
most important factor related to maximum load, while stiff-
ness was mostly related to enzymatic mature or immature
crosslinks, which reflect bone quality [22]. The present results
may reflect an earlier deterioration of bone quality rather than
a decrease of bone volume in AM.
One of the indicators of bone quality evaluated in AM in
the present study was the serum sclerostin level, which was
measured as a parameter of bone formation. Sclerostin is a
glycoprotein secreted from osteocytes. Sclerostin binds to the
low-density lipoprotein receptor-related proteins 5 and 6
(LRP5 and LRP 6) and inhibits bone formation by inhibiting
the canonical Wnt/b-catenin signaling pathway [23]. In the
present study, the serum sclerostin level was lower in AM than
in CM, and there was no positive correlation between serum
sclerostin and BMD. In contrast, serum sclerostin was
significantly negatively correlated with blood glucose. These
results were not consistent with those of previous reports that
showed that the serum level of sclerostin was increased in
patients with type 2 DM and was associated with an increased
risk of vertebral fractures, independently of BMD and bone
turnover [10,24]. The relationship between DM and the serum
sclerostin level has not been clearly elucidated. Gennari et al.
reported that serum sclerostin levels were significantly higher
in the type 2 DM group than in the type 1 DM group or the
normal group [25]. It is known that sclerostin is secreted from
more mature osteocytes, which are deeply embedded osteo-
cytes [26]. In addition, hyperglycemia or deficiency of insulin
induces cell apoptosis and decreases bone formation [27]. In
view of these mechanisms, the present results suggest that the
serum sclerostin level was decreased in AM as a result of
acceleration of dysfunction or apoptosis of osteoblasts or
osteocytes.
The present study has several limitations. First, since only
total tibial BMD was evaluated, the results might not reflect
trabecular BMD, which is more affected in type 1 DM. Further
examinations, such as those using peripheral quantitative
computed tomography (pQCT), which can evaluate both
trabecular and cortical BMD, may be useful. Second, the AM
were young, especially at 14 weeks. There was a significant
difference in serum sclerostin levels between AM and CM
only at 18 weeks of age. The serum sclerostin level was shown
to increase with age in a previous report [28]. Thus, older AM
should be studied to evaluate the effect of type 1 DM. The
lifespan of AM is long, so it is easy to evaluate thecomplications of long-term hyperglycemia in these mice.
Third, histological examinations were not performed. Evalu-
ations of the bone microarchitecture in DM are needed with
bone morphometry or pQCT.
In conclusion, BMD, bone strength, and the serum sclero-
stin level were lower in AM. The serum sclerostin level had a
significant negative correlation with the blood glucose level,
but there was no significant relationship between the serum
sclerostin level and total tibial BMD or bone strength on the
three-point bending test of the femur.
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